Answers are grounded in this paper and cite their sources.
Crystal structure analyses are reported for anhydrous copper(II) hexafluoroacetylacetonate (Cu(hfac)(2)) and for two of its hydrates. The anhydrous compound (Cu(hfac)(2), 1: P1; at 100 K, a = 5.428(1), b = 5.849(1), c = 11.516(3) A; alpha = 81.47(2), beta = 74.57(2), gamma = 86.96(2) degrees; Z = 1) contains centrosymmetric square-planar complexes with close intermolecular Cu.F contacts. The geometry of the complex is similar to that previously reported for Cu(hfac)(2).toluene. The monoaquo compound (Cu(hfac)(2)(H(2)O), 2: P2(1)/c; at 100 K, a = 10.8300(8), b = 6.5400(6), c = 21.551(3) A; beta = 90.282(8) degrees; Z = 4) consists of square-pyramidal molecules with apical H(2)O ligands, and close-lying F atoms in the sixth coordination sites. The major difference between this structure and the two other polymorphs previously reported is the nature and direction of hydrogen bonds. The yellow-green solid formed from Cu(hfac)(2) with excess H(2)O is identified as the trihydrate. In crystalline form it is the previously unreported [trans-Cu(hfac)(2)(H(2)O)(2)].H(2)O (3: P1; at 150 K, a = 8.3899(3), b = 9.6011(3), c = 11.4852(4) A; alpha = 72.397(2), beta = 79.161(2), gamma = 87.843(2) degrees; Z = 2). There is no conclusive evidence in favor of any solid with the composition Cu(hfac)(2).2H(2)O.
No takes yet. Share an insight, caveat, or question.
Maverick et al. (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: